Navigation Links
Edwards Lifesciences' Board Approves New $250 Million Share Repurchase Program

IRVINE, Calif., July 11 /PRNewswire-FirstCall/ -- Edwards Lifesciences Corporation (NYSE: EW), a world leader in products and technologies to treat advanced cardiovascular disease, announced today that its board of directors has authorized a new share repurchase program to acquire up to $250 million of the company's outstanding common shares. Edwards recently completed a $250 million share repurchase program that its board of directors approved in September 2007.

"This new program reaffirms the confidence we have in our future growth prospects, and provides us with an opportunity to continue to increase shareholder value," said Michael A. Mussallem, Edwards Lifesciences' chairman and CEO.

Approximately 2.7 million shares were issued in June 2008 in response to the call for redemption by the company of its $150 million convertible debenture. During the second quarter of 2008, the company repurchased 2.3 million shares for approximately $135 million, partially offsetting the issuance of these shares.

During the first half of 2008, Edwards repurchased a total of 4.6 million shares for approximately $235 million. As of June 30, 2008, the company had approximately 56.2 million shares of common stock outstanding.

The company may repurchase shares in the open market or in privately negotiated transactions. The timing and extent of any repurchase will depend upon market conditions, corporate requirements and other factors.

About Edwards Lifesciences

Edwards Lifesciences is the global leader in the science of heart valves and hemodynamic monitoring. Headquartered in Irvine, Calif., Edwards treats advanced cardiovascular disease with its market-leading heart valve therapies, and critical care and vascular technologies. In 2008, Edwards celebrates 50 years of partnering with clinicians to develop life-saving innovations. The company's global brands, which are sold in approximately 100 countries, include CardioVations, Carpentier-Edwards, Cosgrove-Edwards, FloTrac, Fogarty, PERIMOUNT Magna and Swan-Ganz. Additional company information can be found at

This news release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. These forward-looking statements include, but are not limited to, the company's ability to promptly respond to the FDA's questions and receive an SFA indication by the end of the year. Forward-looking statements are based on estimates and assumptions made by management of the company and are believed to be reasonable, though they are inherently uncertain and difficult to predict.

Forward-looking statements involve risks and uncertainties that could cause actual results or experience to differ materially from that expressed or implied by the forward-looking statements. Factors that could cause actual results or experience to differ materially from that expressed or implied by the forward-looking statements are detailed in the company's filings with the Securities and Exchange Commission including its Annual Report on Form 10-K for the year ended December 31, 2007.

Edwards is a trademark of Edwards Lifesciences Corporation. Edwards Lifesciences, the stylized E logo, CardioVations, Carpentier-Edwards, Cosgrove-Edwards, FloTrac, Fogarty, PERIMOUNT Magna, and Swan-Ganz are trademarks of Edwards Lifesciences Corporation and are registered in the United States Patent and Trademark Office.

SOURCE Edwards Lifesciences Corporation
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Edwards Lifesciences to Present at the Goldman Sachs 29th Annual Global Healthcare Conference
2. Edwards Lifesciences Receives Additional Questions From the FDA About the LifeStent Product Line
3. Aflac to be Primary Sponsor of Carl Edwards and the No. 99 Ford Fusion
4. Edwards Lifesciences Announces Retirement of Director Vernon Loucks
5. Edwards Lifesciences to Host Earnings Conference Call on April 22, 2008
6. Optimal Readings Appoints Operations Veteran Rita Edwards as SVP Clinical Operations
7. Edwards Lifesciences Chairman and CEO Adopts New 10b5-1 Stock Trading Plan to Replace Recently Expired Plan
8. Edwards Lifesciences to Present at the Citi 5th Annual Small and Mid-Cap Conference
9. Edwards Lifesciences to Present at the Cowen and Company Annual Healthcare Conference
10. Edwards Lifesciences Initiates Patent Infringement Litigation Against CoreValve in the U.S.
11. Edwards Lifesciences Reports Strong Fourth Quarter Sales
Post Your Comments:
(Date:10/13/2017)... ... October 13, 2017 , ... Apple Rehab Shelton Lakes , which specializes ... of the facility as part of a disaster drill on October 3rd. , Apple ... Shelton City Emergency Manager, as well as the Connecticut Long Term Care Mutual ...
(Date:10/13/2017)... ... ... Global Healthcare Management’s 4th Annual Kids Fun Run brought out many kids this ... by Global Healthcare Management’s CEO, Jon Letko, is aimed at getting kids excited about ... ages; it is a non-competitive, non-timed event, which is all about having fun and ...
(Date:10/13/2017)... ... October 13, 2017 , ... “The Journey: From the Mountains to the Mission ... lost souls in the Philippines. “The Journey: From the Mountains to the Mission Field” ... the Bible. She has taught all ages and currently teaches a class of ladies ...
(Date:10/12/2017)... ... October 12, 2017 , ... Planet Fitness, one of the largest and ... plans to open a flagship location in Covington, LA at 401 N. U.S. Highway ... store next to Office Depot in the Holiday Square shopping center. Its location allows ...
(Date:10/12/2017)... ... October 12, 2017 , ... Asante, ... post-acute health care, have expanded their existing home health joint venture through an ... has been operating a joint venture home health company with Asante, delivering clinically ...
Breaking Medicine News(10 mins):
(Date:10/12/2017)... Oct. 12, 2017 AVACEN Medical , Inc. ... with their  2017 New Product Innovation Award for Its ... primary and secondary medical device market research by Frost & ... first-to-market OTC, drug-free pain relief product, the AVACEN 100, offers ... treating fibromyalgia widespread pain. ...
(Date:10/11/2017)... , Oct. 11, 2017  Caris Life Sciences ® ... fulfilling the promise of precision medicine, today announced that ... Caris, Precision Oncology Alliance™ (POA) as its 17 th ... the St. Jude Crosson Cancer Institute will help develop ... use of tumor profiling, making cancer treatment more precise ...
(Date:10/10/2017)... Pa. , Oct. 10, 2017   West ... in innovative solutions for injectable drug administration, today shared ... West,s ID Adapter for improving the intradermal administration of ... Fourth Skin Vaccination Summit in May 2017 by Dr. ... Lead, Polio Department, World Health Organization (WHO), and recently ...
Breaking Medicine Technology: